Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1994-10-14
pubmed:abstractText
The overall median survival of women with advanced or high-risk primary breast cancer has not changed with conventional chemotherapy. Regimens employing high-dose chemotherapy with autologous stem cell support (ABMT) have been developed with the hope of optimizing tumor response and increasing survival. Early phase I studies in women with advanced refractory disease achieved high response rates of short duration. Second generation studies combined an induction phase followed by one high-dose intensification at time of maximum tumor response. The Dana-Farber Cancer Institute/Beth Israel Hospitals have developed the high-dose intensification regimen of cyclophosphamide, thiotepa, and carboplatin (CTCb) for use in women with metastatic and high-risk stage IIIB/inflammatory breast cancer. To date, approximately 19% of women with metastatic disease remain progression free using this approach, with median length of follow-up approaching 40 months. Although the median duration of follow-up for the stage IIIB women is much shorter (approximately 12 months), greater than 90% of these women are thus far disease free. With the advent of hematologic support, such as blood stem cells and colony-stimulating factors, the morbidity, mortality, and costs associated with this treatment have been substantially reduced, allowing for two or more cycles of high-dose intensification to be employed, to exploit the potential of dose-intensity to optimize response.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1061-6128
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
507-11
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:7916250-Adenocarcinoma, pubmed-meshheading:7916250-Adult, pubmed-meshheading:7916250-Aged, pubmed-meshheading:7916250-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:7916250-Blood Transfusion, Autologous, pubmed-meshheading:7916250-Bone Marrow Diseases, pubmed-meshheading:7916250-Boston, pubmed-meshheading:7916250-Breast Neoplasms, pubmed-meshheading:7916250-Carboplatin, pubmed-meshheading:7916250-Clinical Trials, Phase I as Topic, pubmed-meshheading:7916250-Clinical Trials, Phase II as Topic, pubmed-meshheading:7916250-Combined Modality Therapy, pubmed-meshheading:7916250-Cyclophosphamide, pubmed-meshheading:7916250-Feasibility Studies, pubmed-meshheading:7916250-Female, pubmed-meshheading:7916250-Hematopoietic Cell Growth Factors, pubmed-meshheading:7916250-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:7916250-Humans, pubmed-meshheading:7916250-Immunologic Factors, pubmed-meshheading:7916250-Middle Aged, pubmed-meshheading:7916250-Neoplasm Staging, pubmed-meshheading:7916250-Pilot Projects, pubmed-meshheading:7916250-Randomized Controlled Trials as Topic, pubmed-meshheading:7916250-Remission Induction, pubmed-meshheading:7916250-Retrospective Studies, pubmed-meshheading:7916250-Survival Analysis, pubmed-meshheading:7916250-Thiotepa, pubmed-meshheading:7916250-Treatment Outcome
pubmed:year
1993
pubmed:articleTitle
High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
pubmed:affiliation
Dana-Farber Cancer Institute, Beth Israel Hospital, Harvard Medical School, Boston, MA 02115.
pubmed:publicationType
Journal Article, Review